GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alkem Laboratories Ltd

Alkem Labs: Q2 FY27 Consolidated Unaudited Financial Results Approved

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 12 Nov 2026, 01:55 PM IST  ·  BSE ID: aadcda22-8863-4ee1-9abf-a30224288638
View Original BSE Filing (PDF)
💡
In Simple Terms
Alkem Laboratories' board has approved its latest financial performance report for the quarter and half year ending September 2026.
🤖 AI Summary
  • Alkem Laboratories' Board approved standalone and consolidated unaudited financial results for Q2 FY27 and H1 FY27.
  • Consolidated results include five subsidiaries with total revenue of Rs. 6,013.9 million for the quarter ended September 30, 2026.
  • These five subsidiaries reported total net profit after tax of Rs. 401.6 million for the quarter ended September 30, 2026.
  • Twenty-eight unreviewed subsidiaries contributed Rs. 1,661.7 million to total revenue for the quarter ended September 30, 2026.
  • These twenty-eight unreviewed subsidiaries recorded a total net loss after tax of Rs. 284.2 million for the quarter.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total Revenue (5 reviewed subsidiaries) - Q2 FY27
Rs. 6,013.9 million
Total Net Profit After Tax (5 reviewed subsidiaries) - Q2 FY27
Rs. 401.6 million
Total Revenue (28 unreviewed subsidiaries) - Q2 FY27
Rs. 1,661.7 million
Total Net Loss After Tax (28 unreviewed subsidiaries) - Q2 FY27
Rs. 284.2 million
🏢 How This Affects the Company
⚠️
Risk Impact
The auditor noted that 28 subsidiaries and one associate, representing Rs. 1,661.7 million in revenue for Q2 FY27, were not reviewed by their auditors, relying on management certification.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based solely on this announcement of results approval.
👤
Who Is Affected
All shareholders are affected as the company's financial results provide insight into its operational and financial health for Q2 FY27.
🔍
Management Signal
The Board's approval indicates the formal release of the company's financial performance for the period ended September 30, 2026.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Review of the full Q2 FY27 unaudited financial statements for detailed performance metrics.
Analysis of future earnings calls for management commentary on unreviewed subsidiaries.
Track future auditor reports for any changes in review scope for subsidiaries.
MEDIUM RISK A significant portion of consolidated revenue (Rs. 1,661.7 million) from 28 subsidiaries was not reviewed by auditors.
💡 Investor Takeaway
Alkem Laboratories' Board approved consolidated unaudited financial results for Q2 FY27. Five reviewed subsidiaries contributed Rs. 6,013.9 million in revenue and Rs. 401.6 million net profit after tax for the quarter. Twenty-eight unreviewed subsidiaries generated Rs. 1,661.7 million revenue and a Rs. 284.2 million net loss after tax.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Auditors did not review 28 subsidiaries, which reflected total revenue of Rs. 1,661.7 million for Q2 FY27, relying on management certifications.
  • The 28 unreviewed subsidiaries recorded a total net loss after tax of Rs. 284.2 million for the quarter ended September 30, 2026.
📅 Company Track Record
Alkem Laboratories reported Q1 FY27 consolidated revenue grew 10.95% to ₹37,401.5 Million with net profit down 21.7%. The Board previously approved Q2 FY27 results, including Rs. 1,661.7 million revenue from unreviewed subsidiaries, on 2026-11-12.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What financial period do Alkem Laboratories' approved results cover?
The approved results cover the quarter and half year ended September 30, 2026, which is Q2 FY27 and H1 FY27.
What was the total revenue from subsidiaries reviewed by other auditors for Q2 FY27?
Five subsidiaries reviewed by other auditors reported total revenues of Rs. 6,013.9 million for the quarter ended September 30, 2026.
What was the total net profit after tax for the five reviewed subsidiaries in Q2 FY27?
These five subsidiaries recorded a total net profit after tax of Rs. 401.6 million for the quarter ended September 30, 2026.
What was the total revenue from subsidiaries not reviewed by auditors for Q2 FY27?
Twenty-eight subsidiaries, not reviewed by their auditors, reflected total revenue of Rs. 1,661.7 million for the quarter ended September 30, 2026.
What was the total net loss after tax for the unreviewed subsidiaries in Q2 FY27?
The twenty-eight unreviewed subsidiaries reported a total net loss after tax of Rs. 284.2 million for the quarter ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.